Selected as a Finalist for the CITELINE Japan Award 2024 Biotech Company of the Year
We are honored to announce that we’ve been chosen as a finalist for the prestigious Biotech...
Read More
Notice of Article Published in the Nikkei
Prism BioLab in the Spotlight for Drug Discovery, Recognized by Major Pharma www.nikkei.com/article/DGXZQOUC06CAK0W4A900C2000000/
Read More
Eisai to Present E7386, co-created by PRISM BioLab and Eisai, at the ESMO (European Society for Medical Oncology) Annual Meeting
TOKYO, Japan, 9 September 2024: -- PRISM BioLab, Co. Ltd. , a leading discovery and development...
Read More
PRISM BioLab opens a business office in Tokyo
We are pleased to announce the establishment of PRISM BioLab Co., Ltd. Tokyo office. The office...
Read More
Announcement of Initial Listing on Tokyo Stock Exchange Growth Market
PRISM BioLab Corporation is pleased to announce its initial listing on the Tokyo Stock Exchange Growth...
Read More
Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange
PRISM BioLab is pleased to announce that the Tokyo Stock Exchange today approved the initial listing...
Read More
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
TOKYO, Japan, 25 Apr 2024: -- PRISM BioLab, Co. Ltd. , a leading discovery and development...
Read More
Announcement of setting the record date for stock split
Announcement of setting the record date for stock split(pdf)
Read More
January 24, 2024
PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions
TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology...
Read More
November 28, 2023
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology...
Read More